Eric and Michelle Crawford have been traveling to Frankfort for several years trying to gain support from state legislators for the legalization of medical cannabis
Rorhabacher said that he hoped Congress won’t just pass another continuing resolution on Feb. 8. “I hope that we come up with an omnibus bill that will include an appropriations bill for the Department of Justice. At that point, then we are safe for eight or nine months. Then hopefully during those eight or nine months, we will pass a regular piece of legislation that will prevent us from jumping through all of these hoops every year.”
Cannabis buds and extracts as well as synthetic cannabinoids have been available on prescription to patients with severe diseases since March 2017, with the costs covered by health insurance companies.The prescription of medical marihuana is not restricted to specific symptoms and is therefore also valid for patients with Parkinson’s disease. From a legal perspective, patients who are seriously ill even have the right to be treated with cannabis if standard treatment methods are unsuccessful or result in unbearable side effects. This also applies even if only a slight chance of noticeable improvement is predicted as a result of the cannabis treatment.
Neil Paine a former soldier who served in Northern Ireland during the Troubles advocates the use of cannabis for medicinal purposes
Weed to deal with morning sickness. Thoughts?
The US has always had a turbulent relationship with cannabis. The substance has often been portrayed as a villainous, addictive, mind-altering drug, with harrowing consequences if used even once,
Health Minister Andrew Green confirmed last year that following advice from the Jersey Misuse of Drugs Advisory Council he was looking into legalising certain medicinal cannabis products and added that he could lodge proposals to legalise certain medicines before the end of 2017.
Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting
In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for administering staff and surrounding patients. Different modes of administration also provide different yet potentially significant issues. One route that has become of clinical interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively safe method of intrapulmonary administration that may be particularly useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. Research results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.
Cannabinoids appear to possess many potential medical uses, which may extend to pain control. A narrative review of the literature has found a variety of studies testing botanical and synthetic cannabinoids in different pain syndromes (acute pain, cancer pain, chronic noncancer pain, fibromyalgia pain, migraine, neuropathic pain, visceral pain, and others). Results from these studies are mixed; cannabinoids appear to be most effective in controlling neuropathic pain, allodynia, medication-rebound headache, and chronic noncancer pain. A great deal more remains to be elucidated about cannabinoids which may emerge to play an important role in the treatment of neuropathic and possibly other painful conditions. There remains a great deal more to learn about the role of cannabinoids in pain management.
Germany’s medical marijuana users are people tired of popping powerful pills to ease pain. Facing a cannabis import crisis, the country is now starting to grow its own.